SERA

SEC source: 0001534969-22-000109 · wf-form4_165654363063215.xml · nonDerivative · entry 3

Boniface John J. · CIK 0001870674 · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 57,410

F1 · kind: The transaction reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 14, 2021.

SEC source: 0001534969-22-000109 · wf-form4_165654363063215.xml · nonDerivative · entry 2

Boniface John J. · CIK 0001870674 · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 58,410

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001534969-22-000109 · wf-form4_165654363063215.xml · nonDerivative · entry 1

Boniface John J. · CIK 0001870674 · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 57,410

F1 · kind: The transaction reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 14, 2021.

F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.70 to $2.57, inclusive. The reporting person will provide to the staff of the Securities and Exchange Commission, the issuer, or any security holder of the issuer, upon request, full information regarding the number of shares sold at each separate price.

SEC source: 0001534969-22-000098 · wf-form4_165584723965194.xml · nonDerivative · entry 1

Boniface John J. · CIK 0001870674 · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 60,135

F1 · kind: The transaction reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 14, 2021.

F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.28 to $1.35, inclusive. The reporting person will provide to the staff of the Securities and Exchange Commission, the issuer, or any security holder of the issuer, upon request, full information regarding the number of shares sold at each separate price.

SEC source: 0001534969-22-000096 · wf-form4_165541075185874.xml · nonDerivative · entry 1

Jackson Benjamin · CIK 0001779964 · General Counsel

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 8,000

F1 · price: The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.18 to $1.22, inclusive. The reporting person will provide to the staff of the Securities and Exchange Commission, the issuer, or any security holder of the issuer, upon request, full information regarding the number of shares purchased at each separate price.

SEC source: 0001534969-22-000095 · wf-form4_165541073026801.xml · nonDerivative · entry 1

Boniface John J. · CIK 0001870674 · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 62,860

F1 · kind: The transaction reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 14, 2021.

F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.16 to $1.28, inclusive. The reporting person will provide to the staff of the Securities and Exchange Commission, the issuer, or any security holder of the issuer, upon request, full information regarding the number of shares sold at each separate price.

SEC source: 0001534969-22-000092 · wf-form4_165463743913647.xml · nonDerivative · entry 1

Boniface John J. · CIK 0001870674 · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 65,585

F1 · kind: The transaction reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 14, 2021.

F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.29 to $1.34, inclusive. The reporting person will provide to the staff of the Securities and Exchange Commission, the issuer, or any security holder of the issuer, upon request, full information regarding the number of shares sold at each separate price.

SEC source: 0001534969-22-000085 · wf-form4_165454906706619.xml · derivative · entry 1

Phillips Joshua · CIK 0001871555 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 149,675

Underlying: Class A Common Stock · 149,675 shares

Expires 2032-06-03

F1 · derivative.exercise_date: Consists of stock options granted pursuant to Sera Prognostics, Inc.'s Non-Employee Director Compensation Policy and its 2021 Equity Incentive Plan. These stock options vest over one year as follows: 1/12 of the original grant amount vests in monthly installments for one year following the vesting commencement date, which is June 3, 2022.

SEC source: 0001534969-22-000090 · wf-form4_165454916376358.xml · derivative · entry 1

Lawrence Sandra AJ · CIK 0001306386 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 149,675

Underlying: Class A Common Stock · 149,675 shares

Expires 2032-06-03

F1 · derivative.exercise_date: Consists of stock options granted pursuant to Sera Prognostics, Inc.'s Non-Employee Director Compensation Policy and its 2021 Equity Incentive Plan. These stock options vest over one year as follows: 1/12 of the original grant amount vests in monthly installments for one year following the vesting commencement date, which is June 3, 2022.

SEC source: 0001534969-22-000089 · wf-form4_165454914652337.xml · derivative · entry 1

Trimble Ryan · CIK 0001871513 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 149,675

Underlying: Class A Common Stock · 149,675 shares

Expires 2032-06-03

F1 · derivative.exercise_date: Consists of stock options granted pursuant to Sera Prognostics, Inc.'s Non-Employee Director Compensation Policy and its 2021 Equity Incentive Plan. These stock options vest over one year as follows: 1/12 of the original grant amount vests in monthly installments for one year following the vesting commencement date, which is June 3, 2022.

SEC source: 0001534969-22-000088 · wf-form4_165454912552594.xml · derivative · entry 1

Lindgardt Zhenya · CIK 0001891299 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 149,675

Underlying: Class A Common Stock · 149,675 shares

Expires 2032-06-03

F1 · derivative.exercise_date: Consists of stock options granted pursuant to Sera Prognostics, Inc.'s Non-Employee Director Compensation Policy and its 2021 Equity Incentive Plan. These stock options vest over one year as follows: 1/12 of the original grant amount vests in monthly installments for one year following the vesting commencement date, which is June 3, 2022.

SEC source: 0001534969-22-000087 · wf-form4_165454910412913.xml · derivative · entry 1

Kamdar Kim P. · CIK 0001535065 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 149,675

Underlying: Class A Common Stock · 149,675 shares

Expires 2032-06-03

F1 · derivative.exercise_date: Consists of stock options granted pursuant to Sera Prognostics, Inc.'s Non-Employee Director Compensation Policy and its 2021 Equity Incentive Plan. These stock options vest over one year as follows: 1/12 of the original grant amount vests in monthly installments for one year following the vesting commencement date, which is June 3, 2022.

SEC source: 0001534969-22-000086 · wf-form4_165454908463160.xml · derivative · entry 1

Mirza Mansoor Raza · CIK 0001588389 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 149,675

Underlying: Class A Common Stock · 149,675 shares

Expires 2032-06-03

F1 · derivative.exercise_date: Consists of stock options granted pursuant to Sera Prognostics, Inc.'s Non-Employee Director Compensation Policy and its 2021 Equity Incentive Plan. These stock options vest over one year as follows: 1/12 of the original grant amount vests in monthly installments for one year following the vesting commencement date, which is June 3, 2022.

SEC source: 0001534969-22-000076 · wf-form4_165411969787689.xml · derivative · entry 4

Boniface John J. · CIK 0001870674 · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,844

Underlying: Class A Common Stock · 1,000 shares

Expires 2022-09-11

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F4 · derivative.exercise_date: The shares subject to this option are fully vested and exercisable.

SEC source: 0001534969-22-000076 · wf-form4_165411969787689.xml · nonDerivative · entry 3

Boniface John J. · CIK 0001870674 · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 68,310

F1 · kind: The transaction reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 14, 2021.

F3 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.32 to $1.41, inclusive. The reporting person will provide to the staff of the Securities and Exchange Commission, the issuer, or any security holder of the issuer, upon request, full information regarding the number of shares sold at each separate price.

SEC source: 0001534969-22-000076 · wf-form4_165411969787689.xml · nonDerivative · entry 2

Boniface John J. · CIK 0001870674 · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 69,310

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001534969-22-000076 · wf-form4_165411969787689.xml · nonDerivative · entry 1

Boniface John J. · CIK 0001870674 · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 68,310

F1 · kind: The transaction reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 14, 2021.

F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.38 to $1.49, inclusive. The reporting person will provide to the staff of the Securities and Exchange Commission, the issuer, or any security holder of the issuer, upon request, full information regarding the number of shares sold at each separate price.

SEC source: 0001534969-22-000074 · wf-form4_165343056027334.xml · nonDerivative · entry 1

Boniface John J. · CIK 0001870674 · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 71,035

F1 · kind: The transaction reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 14, 2021.

F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.50 to $1.57, inclusive. The reporting person will provide to the staff of the Securities and Exchange Commission, the issuer, or any security holder of the issuer, upon request, full information regarding the number of shares sold at each separate price.

SEC source: 0001534969-22-000072 · wf-form4_165282724384796.xml · nonDerivative · entry 1

Boniface John J. · CIK 0001870674 · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 73,760

F1 · kind: The transaction reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 14, 2021.

F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.50 to $1.64, inclusive. The reporting person will provide to the staff of the Securities and Exchange Commission, the issuer, or any security holder of the issuer, upon request, full information regarding the number of shares sold at each separate price.

SEC source: 0001534969-22-000070 · wf-form4_165222284201007.xml · nonDerivative · entry 1

Boniface John J. · CIK 0001870674 · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 76,485

F1 · kind: The transaction reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 14, 2021.

SEC source: 0001534969-22-000064 · wf-form4_165170239136811.xml · derivative · entry 3

Boniface John J. · CIK 0001870674 · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 3,844

Underlying: Class A Common Stock · 1,000 shares

Expires 2022-09-11

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_date: The shares subject to this option are fully vested and exercisable.

SEC source: 0001534969-22-000064 · wf-form4_165170239136811.xml · nonDerivative · entry 2

Boniface John J. · CIK 0001870674 · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 79,210

F1 · kind: The transaction reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 14, 2021.

F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $2.11 to $2.30, inclusive. The reporting person will provide to the staff of the Securities and Exchange Commission, the issuer, or any security holder of the issuer, upon request, full information regarding the number of shares sold at each separate price.

SEC source: 0001534969-22-000064 · wf-form4_165170239136811.xml · nonDerivative · entry 1

Boniface John J. · CIK 0001870674 · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 80,210

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001534969-22-000062 · wf-form4_165161417543531.xml · nonDerivative · entry 1

Boniface John J. · CIK 0001870674 · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 79,210

F1 · kind: The transaction reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 14, 2021.

F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $2.12 to $2.23, inclusive. The reporting person will provide to the staff of the Securities and Exchange Commission, the issuer, or any security holder of the issuer, upon request, full information regarding the number of shares sold at each separate price.

SEC source: 0001534969-22-000060 · wf-form4_165101209655230.xml · nonDerivative · entry 1

Boniface John J. · CIK 0001870674 · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 81,935

F1 · kind: The transaction reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 14, 2021.

F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $2.10 to $2.31, inclusive. The reporting person will provide to the staff of the Securities and Exchange Commission, the issuer, or any security holder of the issuer, upon request, full information regarding the number of shares sold at each separate price.

SEC source: 0001534969-22-000054 · wf-form4_165048695567483.xml · nonDerivative · entry 1

Boniface John J. · CIK 0001870674 · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 84,660

F1 · kind: The transaction reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 14, 2021.

F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.98 to $2.21, inclusive. The reporting person will provide to the staff of the Securities and Exchange Commission, the issuer, or any security holder of the issuer, upon request, full information regarding the number of shares sold at each separate price.

SEC source: 0001534969-22-000052 · wf-form4_164988158779641.xml · nonDerivative · entry 1

Boniface John J. · CIK 0001870674 · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 87,385

F1 · kind: The transaction reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 14, 2021.

F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $2.50 to $2.84, inclusive. The reporting person will provide to the staff of the Securities and Exchange Commission, the issuer, or any security holder of the issuer, upon request, full information regarding the number of shares sold at each separate price.

SEC source: 0001534969-22-000050 · wf-form4_164979854182714.xml · derivative · entry 1

Barlow Jane F · CIK 0001736026 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 140,823

Underlying: Class A Common Stock · 140,823 shares

Expires 2032-04-11

F1 · derivative.exercise_date: These stock options vest over three years as follows: 1/36 of the original grant amount vests in monthly installments for three years following the vesting commencement date, which is April 11, 2022.

SEC source: 0001534969-22-000044 · wf-form4_164936217180631.xml · derivative · entry 4

Boniface John J. · CIK 0001870674 · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 4,844

Underlying: Class A Common Stock · 1,000 shares

Expires 2022-09-11

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F4 · derivative.exercise_date: The shares subject to this option are fully vested and exercisable.

SEC source: 0001534969-22-000044 · wf-form4_164936217180631.xml · nonDerivative · entry 3

Boniface John J. · CIK 0001870674 · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 90,110

F1 · kind: The transaction reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 14, 2021.

F3 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $2.88 to $3.19, inclusive. The reporting person will provide to the staff of the Securities and Exchange Commission, the issuer, or any security holder of the issuer, upon request, full information regarding the number of shares sold at each separate price.

SEC source: 0001534969-22-000044 · wf-form4_164936217180631.xml · nonDerivative · entry 2

Boniface John J. · CIK 0001870674 · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 91,110

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001534969-22-000044 · wf-form4_164936217180631.xml · nonDerivative · entry 1

Boniface John J. · CIK 0001870674 · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 90,110

F1 · kind: The transaction reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 14, 2021.

F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $3.25 to $3.53, inclusive. The reporting person will provide to the staff of the Securities and Exchange Commission, the issuer, or any security holder of the issuer, upon request, full information regarding the number of shares sold at each separate price.

SEC source: 0001534969-22-000038 · wf-form4_164867081882345.xml · nonDerivative · entry 1

Boniface John J. · CIK 0001870674 · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 92,835

F1 · kind: The transaction reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 14, 2021.

F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $3.63 to $3.81, inclusive. The reporting person will provide to the staff of the Securities and Exchange Commission, the issuer, or any security holder of the issuer, upon request, full information regarding the number of shares sold at each separate price.

SEC source: 0001534969-22-000022 · wf-form4_164824050185394.xml · derivative · entry 1

Altomare Nadia · CIK 0001871553 · Chief Commercial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 75,735

Underlying: Class A Common Stock · 75,735 shares

Expires 2032-03-23

F1 · derivative.exercise_date: These stock options vest over four years beginning on the grant date of March 23, 2022 as follows: 15% of the original grant amount vests in equal monthly installments over the first year following the grant date, 20% of the original grant amount vests in equal monthly installments over the second year following the grant date, 25% of the original grant amount vests in equal monthly installments over the third year following the grant date, and 40% of the original grant amount vests in equal monthly installments over the fourth year following the grant date, subject to the reporting person continuing to provide services to the issuer.

SEC source: 0001534969-22-000021 · wf-form4_164824047308209.xml · derivative · entry 1

Harrison Robert Gardner · CIK 0001421563 · Chief Information Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 33,698

Underlying: Class A Common Stock · 33,698 shares

Expires 2032-03-23

F1 · derivative.exercise_date: These stock options vest over four years beginning on the grant date of March 23, 2022 as follows: 15% of the original grant amount vests in equal monthly installments over the first year following the grant date, 20% of the original grant amount vests in equal monthly installments over the second year following the grant date, 25% of the original grant amount vests in equal monthly installments over the third year following the grant date, and 40% of the original grant amount vests in equal monthly installments over the fourth year following the grant date, subject to the reporting person continuing to provide services to the issuer.

SEC source: 0001534969-22-000023 · wf-form4_164824052547856.xml · derivative · entry 1

CRITCHFIELD GREGORY C · CIK 0001191080 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 429,225

Underlying: Class A Common Stock · 429,225 shares

Expires 2032-03-23

F1 · derivative.exercise_date: These stock options vest over four years beginning on the grant date of March 23, 2022 as follows: 15% of the original grant amount vests in equal monthly installments over the first year following the grant date, 20% of the original grant amount vests in equal monthly installments over the second year following the grant date, 25% of the original grant amount vests in equal monthly installments over the third year following the grant date, and 40% of the original grant amount vests in equal monthly installments over the fourth year following the grant date, subject to the reporting person continuing to provide services to the issuer.

SEC source: 0001534969-22-000019 · wf-form4_164824040790992.xml · derivative · entry 1

MOYES JAY M · CIK 0001191062 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 168,275

Underlying: Class A Common Stock · 168,275 shares

Expires 2032-03-23

F1 · derivative.exercise_date: These stock options vest over four years beginning on the grant date of March 23, 2022 as follows: 15% of the original grant amount vests in equal monthly installments over the first year following the grant date, 20% of the original grant amount vests in equal monthly installments over the second year following the grant date, 25% of the original grant amount vests in equal monthly installments over the third year following the grant date, and 40% of the original grant amount vests in equal monthly installments over the fourth year following the grant date, subject to the reporting person continuing to provide services to the issuer.

SEC source: 0001534969-22-000024 · wf-form4_164824061611396.xml · derivative · entry 1

Jackson Benjamin · CIK 0001779964 · General Counsel

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 60,345

Underlying: Class A Common Stock · 60,345 shares

Expires 2032-03-23

F1 · derivative.exercise_date: These stock options vest over four years beginning on the grant date of March 23, 2022 as follows: 15% of the original grant amount vests in equal monthly installments over the first year following the grant date, 20% of the original grant amount vests in equal monthly installments over the second year following the grant date, 25% of the original grant amount vests in equal monthly installments over the third year following the grant date, and 40% of the original grant amount vests in equal monthly installments over the fourth year following the grant date, subject to the reporting person continuing to provide services to the issuer.

SEC source: 0001534969-22-000020 · wf-form4_164824045068286.xml · derivative · entry 1

Boniface John J. · CIK 0001870674 · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 121,705

Underlying: Class A Common Stock · 121,705 shares

Expires 2032-03-23

F1 · derivative.exercise_date: These stock options vest over four years beginning on the grant date of March 23, 2022 as follows: 15% of the original grant amount vests in equal monthly installments over the first year following the grant date, 20% of the original grant amount vests in equal monthly installments over the second year following the grant date, 25% of the original grant amount vests in equal monthly installments over the third year following the grant date, and 40% of the original grant amount vests in equal monthly installments over the fourth year following the grant date, subject to the reporting person continuing to provide services to the issuer.

SEC source: 0001534969-22-000018 · wf-form4_164824038286772.xml · derivative · entry 1

Kearney Paul · CIK 0001888075 · Chief Data Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 30,426

Underlying: Class A Common Stock · 30,426 shares

Expires 2032-03-23

F1 · derivative.exercise_date: These stock options vest over four years beginning on the grant date of March 23, 2022 as follows: 15% of the original grant amount vests in equal monthly installments over the first year following the grant date, 20% of the original grant amount vests in equal monthly installments over the second year following the grant date, 25% of the original grant amount vests in equal monthly installments over the third year following the grant date, and 40% of the original grant amount vests in equal monthly installments over the fourth year following the grant date, subject to the reporting person continuing to provide services to the issuer.

SEC source: 0001534969-22-000010 · wf-form4_164806629160651.xml · nonDerivative · entry 1

Boniface John J. · CIK 0001870674 · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 95,560

F1 · kind: The transaction reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 14, 2021.

F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $3.59 to $3.82, inclusive. The reporting person will provide to the staff of the Securities and Exchange Commission, the issuer, or any security holder of the issuer, upon request, full information regarding the number of shares sold at each separate price.

SEC source: 0001534969-22-000008 · wf-form4_164738149272802.xml · nonDerivative · entry 1

Boniface John J. · CIK 0001870674 · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 98,285

F1 · kind: The transaction reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 14, 2021.

SEC source: 0001534969-22-000006 · wf-form4_164728880705549.xml · derivative · entry 2

Boniface John J. · CIK 0001870674 · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Class A Common Stock · 75,998 shares

Expires 2022-03-14

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_date: The shares subject to this option are fully vested and exercisable.

SEC source: 0001534969-22-000006 · wf-form4_164728880705549.xml · nonDerivative · entry 1

Boniface John J. · CIK 0001870674 · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 101,010

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001534969-22-000004 · wf-form4_164367039214000.xml · derivative · entry 1

Foley Michael R · CIK 0001892321 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 276,000

Underlying: Class A Common Stock · 276,000 shares

Expires 2032-01-28

F1 · derivative.exercise_date: These stock options vest over four years as follows: 25% of the original grant amount vests on the first anniversary of the vesting commencement date, which is January 28, 2022, and 1/36 of the remaining amount vests in monthly installments for three years thereafter.

SEC source: 0001534969-21-000027 · wf-form4_163884334581990.xml · derivative · entry 2

Boniface John J. · CIK 0001870674 · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Class A Common Stock · 25,012 shares

Expires 2021-12-15

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_date: The shares subject to this option are fully vested and exercisable.

SEC source: 0001534969-21-000027 · wf-form4_163884334581990.xml · nonDerivative · entry 1

Boniface John J. · CIK 0001870674 · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 25,012

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001534969-21-000025 · wf-form4_163830664358177.xml · derivative · entry 1

Lawrence Sandra AJ · CIK 0001306386 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 40,332

Underlying: Class A Common Stock · 40,332 shares

Expires 2031-11-29

F1 · derivative.exercise_date: These stock options vest over three years as follows: 1/36 of the original grant amount vests in monthly installments for three years following the vesting commencement date, which is November 29, 2021.

SEC source: 0001534969-21-000019 · wf-form4_163649303517227.xml · derivative · entry 1

Lindgardt Zhenya · CIK 0001891299 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 38,325

Underlying: Class A Common Stock · 38,325 shares

Expires 2031-11-08

F1 · derivative.exercise_date: These stock options vest over three years as follows: 1/36 of the original grant amount vests in monthly installments for three years following the vesting commencement date, which is November 8, 2021.

SEC source: 0001534969-21-000008 · wf-form4_163580609292227.xml · derivative · entry 1

Kearney Paul · CIK 0001888075 · Chief Data Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 107,000

Underlying: Class A Common Stock · 107,000 shares

Expires 2031-11-01

F1 · derivative.exercise_date: These stock options vest over four years as follows: 25% of the original grant amount vests on the first anniversary of the vesting commencement date and 1/36 of the remaining amount vests in monthly installments for three years following the grant date.